• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in development and commercialization of OCR-002 (ornithine phenylacetate0 in intravenous and oral formulations. The company was founded by Wu Xiaoyun, John C. Kappes, and Eckard Weber on January 12, 1998 and is headquartered in Palo Alto, CA.
| Market Cap | 47.46 Million | Shares Outstanding | 26.514 Million | Avg 30-day Volume | 371.716 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.24 |
| Price to Revenue | 59.0354 | Debt to Equity | 1.9176 | EBITDA | -24.009 Million |
| Price to Book Value | 7.8611 | Operating Margin | -4552.7344 | Enterprise Value | 23.247 Million |
| Current Ratio | 1.274 | EPS Growth | 0.289 | Quick Ratio | 1.222 |
| 1 Yr BETA | 1.0222 | 52-week High/Low | 0.0 / | Profit Margin | -4733.9844 |
| Operating Cash Flow Growth | 4.1991 | Altman Z-Score | -19.2392 | Free Cash Flow to Firm | -17.149 Million |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2017-12-11 | 0 | |
|
No longer subject to file | 2017-12-11 | 0 | |
|
No longer subject to file | 2017-12-11 | 0 | |
|
No longer subject to file | 2017-12-11 | 0 | |
|
No longer subject to file | 2017-12-11 | 0 | |
|
0 | 2017-12-11 | 0 | |
|
0 | 2017-12-11 | 0 | |
|
0 | 2017-12-11 | 0 | |
|
0 | 2017-12-11 | 0 | |
|
0 | 2017-12-11 | 0 | |
|
0 | 2017-12-11 | 0 | |
|
GRAIS LINDA S PRESIDENT AND CEO |
|
0 | 2017-12-11 | 0 |
|
BYRNES MICHAEL CFO AND TREASURER |
|
0 | 2017-12-11 | 0 |
|
BUKOFZER STAN CHIEF MEDICAL OFFICER |
|
0 | 2017-12-11 | 0 |
|
THOMAS, MCNERNEY & PARTNERS, LLC THOMAS, MCNERNEY & PARTNERS II L.P. |
|
No longer subject to file | 2017-01-30 | 0 |
|
0 | 2016-12-31 | 0 | |
|
AGGARWAL GAURAV CHIEF BUSINESS OFFICER |
|
20,000 | 2016-01-15 | 0 |
|
PATNI RAJIV CHIEF DEVELOPMENT OFFICER |
|
5,050 | 2015-05-07 | 0 |
|
47,963 | 2015-01-01 | 0 | |
|
TETLOW SHARON ACTING CFO & TREASURER |
|
3,000 | 2014-07-11 | 0 |
|
0 | 2014-06-11 | 0 | |
|
0 | 2014-06-11 | 0 | |
|
SOFINNOVA VENTURE PARTNERS VI L P SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG SOFINNOVA VENTURE AFFILIATES VI LP |
|
No longer subject to file | 2014-03-18 | 0 |
|
ROUSSEAU FRANCK CHIEF MEDICAL & DEV OFFICER |
|
0 | 2013-12-19 | 0 |
|
HILLEMAN JERYL L CFO AND SECRETARY |
|
0 | 2013-12-19 | 0 |
|
0 | 2013-12-19 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
47,963 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
2,438,569 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
2,438,569 | 2013-07-15 | 0 | |
|
1,565,463 | 2013-07-15 | 0 | |
|
15,731 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
2,438,569 | 2013-07-15 | 0 | |
|
7,333 | 2013-07-15 | 0 | |
|
988,285 | 2013-07-15 | 0 | |
|
No longer subject to file | 2013-07-15 | 0 | |
|
47,963 | 2013-07-15 | 0 | |
|
MCGOWAN DANA S. CFO AND SECRETARY |
|
0 | 2013-07-15 | 0 |
|
STANLEY RHONDA L. CONTROLLER |
|
0 | 2013-01-04 | 0 |
|
0 | 2012-08-07 | 0 | |
|
0 | 2012-08-07 | 0 | |
|
THOMAS HELMUT SENIOR VP, R&D |
|
0 | 2012-08-07 | 0 |
|
EISENSTADT RICHARD I VP, FINANCE & CFO |
|
0 | 2012-08-07 | 0 |
|
GARG VIPIN K PRESIDENT & CEO |
|
0 | 2012-08-07 | 0 |
|
0 | 2012-08-07 | 0 | |
|
MOORE DAVID VP, COMMERCIAL OPERATIONS |
|
0 | 2012-04-19 | 0 |
|
232,011 | 2012-03-12 | 0 | |
|
2,328,863 | 2012-03-12 | 0 | |
|
57,704 | 2012-03-12 | 0 | |
|
0 | 2011-04-19 | 0 | |
|
KOSUTIC GORDANA VP, CLINICAL AND REGULATORY |
|
0 | 2011-04-19 | 0 |
|
3,002,291 | 2011-04-06 | 0 | |
|
2,564,791 | 2011-04-06 | 0 | |
|
3,002,286 | 2011-04-06 | 0 | |
|
No longer subject to file | 2011-04-06 | 0 | |
|
No longer subject to file | 2011-04-06 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
